Post by City of Hope
159,779 followers
Fifteen years ago, long-term survival in lung cancer was not something oncologists planned around. That is starting to change. Kristin Higgins, MD, chief clinical officer at City of Hope Cancer Center Atlanta and radiation oncologist, has watched targeted therapy reshape outcomes for patients with specific genetic mutations in non-small cell lung cancer. The latest long-term data from the CROWN study showed that patients with ALK-mutated disease treated with lorlatinib had not yet reached median progression-free survival. For Dr. Higgins, those results signal something the field has not been able to say before. Lung cancer now has long-term survivors. And for the first time, oncologists can start building survivorship care to match. This special edition of On the Edge of Breakthrough: Voices of Cancer Research is out now. Dr. Higgins joins Sumanta Pal, MD, FASCO, Alan Bryce, M.D. and Joseph Mikhael, M.D. for a conversation recorded live at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. YouTube: https://lnkd.in/e5xGtbs9 Apple Podcasts: https://lnkd.in/ezvcmagg Spotify: https://lnkd.in/eAWz8q8J #ASCO26
Video Content